Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
67.99
+3.14 (4.84%)
Sep 18, 2025, 9:11 AM EDT - Market open
Cidara Therapeutics Revenue
In the year 2024, Cidara Therapeutics had annual revenue of $1.28M, down -94.52%.
Revenue (ttm)
$1.28M
Revenue Growth
-94.52%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
1.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -22.01M | -94.52% |
| Dec 31, 2023 | 23.28M | -213.00K | -0.91% |
| Dec 31, 2022 | 23.50M | -26.08M | -52.60% |
| Dec 31, 2021 | 49.57M | 37.51M | 310.81% |
| Dec 31, 2020 | 12.07M | -8.85M | -42.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CDTX News
- 1 day ago - Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting - GlobeNewsWire
- 8 days ago - Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Cidara Therapeutics to Participate in September Investor Conferences - GlobeNewsWire
- 15 days ago - Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting - GlobeNewsWire
- 4 weeks ago - Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout - Seeking Alpha
- 5 weeks ago - Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 - GlobeNewsWire